Mechanisms and Potential Interventions Associated With the Cardiotoxicity of ErbB2-Targeted Drugs: Insights From in vitro, in vivo, and Clinical Studies in Breast Cancer Patients

This review article focuses on the mechanism and potential interventions associated with the cardiotoxicity of ErbB2-targeted drugs—including trastuzumab, lapatinib, pertuzumab, and trastuzumab emtansine—based on currently available evidence from in vitro, in vivo, and clinical studies.

Cellular and Molecular Life Sciences